Ladenburg downgraded Tryp Therapeutics to Neutral from Buy without a price target after the company signed a definitive agreement with Exopharm Limited in which Exopharm intended to acquire all issued and outstanding Tryp common shares for C$0.08 per share. With the agreement unanimously approved by both boards the firm downgraded Tryp Therapeutics.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>